Investors give Orum Therapeutics' unique take on protein degraders another nudge toward the clinic
While protein degraders have seen an influx of cash in recent years, small molecule drugs can run into toxicity problems, due to their difficulty differentiating healthy cells from cancerous ones, Sung Joo Lee said. His company Orum Therapeutics thinks it has a solution — and the idea has investors reaching a little deeper into their pockets.
Orum closed its Series B round for the second time on Wednesday morning, raking in an extra $54 million. The team had initially raised $30 million back in 2019, and the successive round came as the result of ongoing “organic discussion” with existing investors, according to CFO Jae Won Kim.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.